Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Switching of biologic agents and biosimilars

Published bySabina Holubová Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Switching of biologic agents and biosimilars"— Presentation transcript:

1 Figure 2 Switching of biologic agents and biosimilars
Figure 2 | Switching of biologic agents and biosimilars. Switching is a decision by the treating physician to exchange one medicine for another. Currently, physicians often need to decide about switching from the innovator biologic agent to a biosimilar. In the future, they will need to also consider a switch in the opposite direction (reverse-switch), or from one biosimilar to another (cross-switch). Danese, S. et al. (2016) Biosimilars in IBD: from theory to practice Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 2 Switching of biologic agents and biosimilars"

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Low-grade inflammation in FGID

Figure 3 Low-grade inflammation in FGID
Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 4 The gut microbiota directly influences T-cell differentiation
Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Patients cured of HCV infection

Figure 1 Patients cured of HCV infection
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Giant lipid droplet formation

Figure 4 Giant lipid droplet formation
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Schematic outlining the results of Buffington et al.

Figure 1 Schematic outlining the results of Buffington et al.

Similar presentations

Ads by Google